Foghorn Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2024, the following Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K of the Securities Act of 1933) were adopted by our directors and officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934), each of which was intended to satisfy the affirmative defense of Rule10b5-1(c):
On March 11, Steven Bellon, our Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement. Dr. Bellon’s trading arrangement provides for the sale of up to 60,000 shares of our common stock through March 10, 2025.
On March 11, Carlos Costa, our Chief People Officer, adopted a Rule 10b5-1 trading arrangement. Mr. Costa’s trading arrangement provides for the sale of up to 213,106 shares of our common stock through March 10, 2025.
During the three months ended March 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) entered into, modified (as to amount, price or timing of trades) or terminated any non-Rule 10b5-1 trading arrangements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.